SUPER STRENGTH MOTRIN IB LIQUID GELS CAPSULE

Страна: Канада

мова: англійська

Джерело: Health Canada

Активний інгредієнт:

IBUPROFEN

Доступна з:

MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC

Код атс:

M01AE01

ІПН (Міжнародна Ім'я):

IBUPROFEN

Дозування:

400MG

Фармацевтична форма:

CAPSULE

Склад:

IBUPROFEN 400MG

Адміністрація маршрут:

ORAL

Одиниць в упаковці:

12/16/24/50/100/144/165/180

Тип рецепту:

OTC

Терапевтична области:

OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS

Огляд продуктів:

Active ingredient group (AIG) number: 0108883002; AHFS:

Статус Авторизація:

CANCELLED POST MARKET

Дата Авторизація:

2019-07-31

Характеристики продукта

Page 1 of 37
PRODUCT MONOGRAPH
SUPER STRENGTH MOTRIN® IB LIQUID GELS
Ibuprofen Capsules
400 mg
Analgesic /Antipyretic
McNeil Consumer Healthcare
DATE OF PREPARATION:
division of Johnson & Johnson Inc.
October 7, 2008
88 McNabb Street
Markham, Canada
L3R 5L2
DATE OF REVISION:
September 13, 2012
www.motrin.ca
CONTROL NUMBER: 156425
Page 2 of 37
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
....................................................... 3
SUMMARY PRODUCT INFORMATION
.............................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................
3
CONTRAINDICATIONS
........................................................................................................
4
WARNINGS AND PRECAUTIONS
.......................................................................................
5
ADVERSE REACTIONS
.........................................................................................................
9
DRUG INTERACTIONS
.......................................................................................................
13
DOSAGE AND ADMINISTRATION
...................................................................................
16
OVERDOSAGE
......................................................................................................................
16
ACTION AND CLINICAL
PHARMACOLOGY..................................................................
17
STORAGE AND STABILITY
...............................................................................................
20
SPECIAL HANDLING INSTRUCTIONS
............................................................................
20
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................. 20
PART II: SCIENTIFIC INFORMATION
.............................................................................
21
PHARMACEUTICAL INFORMATION
...........................................................